Clinical experience with daptomycin in patients with orthopedic-related infections

Infectious Diseases in Clinical Practice

Volumn 14, Issue 3, 2006, Pages 144-149

  Antony, Suresh J ^a   Angelos, Erin ^a   Stratton, Charles W ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN; DAPTOMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; QUINUPRISTIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; BACTEREMIA; BONE INFECTION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISKITIS; DRUG EFFICACY; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; LAMINECTOMY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PROSTHESIS INFECTION; RETROSPECTIVE STUDY; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT DURATION; TREATMENT OUTCOME; WOUND INFECTION;

EID: 33744485005     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000206490.05422.df     Document Type: Review

References (30)

1. Cubicin®(daptomycin for injection) prescribing information. Lexington, MA: Cubist Pharmaceuticals; September 2003. Report No.: 1108090803.
2. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001;45(6):1919-1922.
3. Fluit AC, Schmitz FJ, Verhoef J, et al. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother. 2004;48(3):1007-1011.
4. Snydman DR, Jacobus NV, McDermott LA, et al. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother. 2000;44(12):3447-3450.
5. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis. 2004;38(7):994-1000.
6. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(8):2538-2544.
7. Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45(6):1799-1802.
8. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49(5):2152.
9. Sabol K, Patterson JE, Lewis JS, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49(4):1664-1665.
10. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058-1060.
11. Livesley NJ, Chow AW. Infected pressure ulcers in elderly individuals. Clin Infect Dis. 2002;35(11):1390-1396.
12. Lipsky BA, Pecoraro RE, Ahroni JH. Foot ulceration and infections in elderly patients with diabetes. Clin Geriatr Med. 1990;6(4):747-769.
13. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9(3):127-138.
14. Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother. 2004;53(6):928-935.
15. Trampuz A, Zimmerli W. New strategies for the treatment of infections associated with prosthetic joints. Curr Opin Investig Drugs. 2005;6(2):185-190.
16. Bernard L, Hoffmeyer P, Assal M, et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother. 2004;53(2):127-129.
17. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structured infections. Clin Infect Dis. 2004;38(12):1673-1681.
18. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55(2):240-245.
19. Naber KG, Eisenstein BI, Tally FP. Daptomycin versus ciprofloxacin in treatment of complicated urinary tract infection due to Gram-positive bacteria. Infect Dis Clin Pract. 2004;12(6):322-327.
20. Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(5):1714-1718.
21. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 1989;33(5):689-692.
22. Vaudaux P, Francois P, Bisognano C, et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother. 2003;52(1):89-95.
23. Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis. 2003;36(9):1157-1161.
24. van de Belt H, Neut D, Schenk W, et al. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthop Scand. 2001;72(6):557-571.
25. Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis. 1998;27(5):1247-1254.
26. Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39(2):235-240.
27. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537-1541.
28. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother. 1998;42(12):3086-3091.
29. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother. 2000;46(5):775-784.
30. Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55(3):387-390.